Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : Working With Immusoft to Develop B-Cell Therapies for Rare Neurometabolic Disorders

10/14/2021 | 05:02am EST


ę MT Newswires 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
12/03Takeda's LIVTENCITYTM (maribavir) Now Available for Certain Individuals Ages 12 Years a..
AQ
12/03Japanese Shares Close With Gains on Japan Services Data
MT
12/02Takeda Says Livtencity Commercially Available in the US for Patients 12 Years and Older
MT
12/02Takeda's LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Ye..
BU
12/02Takeda Pharmaceutical Company Limited Announces its LIVTENCITY? Now Available for Certa..
CI
12/02Takeda Pharmaceutical Buys Back Shares for $441 Million
MT
12/01GENERAL ANNOUNCEMENT : :Takeda Provides Update on Status of Acquisition of Own Shares
PU
12/01TAKEDA PHARMACEUTICAL : Provides Update on Status of Acquisition of Own Shares
PU
11/30Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduc..
BU
11/30GENERAL ANNOUNCEMENT : :The 145th Interim Business Report (April 1, 2021 - September 30, 2..
PU
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 407 B 30 213 M 30 213 M
Net income 2022 223 B 1 973 M 1 973 M
Net Debt 2022 3 334 B 29 566 M 29 566 M
P/E ratio 2022 21,4x
Yield 2022 5,86%
Capitalization 4 782 B 42 287 M 42 398 M
EV / Sales 2022 2,38x
EV / Sales 2023 2,25x
Nbr of Employees 47 099
Free-Float 98,2%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 070,00 JPY
Average target price 4 322,86 JPY
Spread / Average Target 40,8%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-18.24%42 287
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641